Sleep Apnea Linked to Memory and Thinking Problems

A new study suggests that people with symptoms of sleep apnea may be more likely to experience memory or thinking issues, adding to the growing awareness of how sleep quality affects brain health. While the study doesn't prove that sleep apnea causes cognitive decline, it highlights a significant association that deserves further attention.
Sleep apnea is a common but often underdiagnosed disorder where breathing repeatedly stops and starts during sleep. Symptoms include snorting, gasping, and breathing pauses, often accompanied by morning headaches, fatigue, and trouble focusing. These repeated disruptions in breathing can lower oxygen levels in the blood, which may affect brain function over time. Researchers at Boston Medical Center analyzed data from over 4,200 adults who completed surveys on their sleep patterns and cognitive function. Among the participants, 1,079 reported symptoms of sleep apnea. Of these, 33% also reported having memory or thinking problems compared to just 20% of those without sleep apnea symptoms. After adjusting for factors such as age, gender, race, and education, the researchers found that individuals with sleep apnea symptoms were 50% more likely to report cognitive issues. Although the study relies on self-reported data and further research is needed to establish a direct cause-and-effect relationship, it sends a clear message: poor sleep may be a warning sign of deeper health concerns. Regular screening for sleep apnea, especially for those with cognitive complaints, could be a crucial step toward preserving long-term brain health.

Return to top

Lipid Profile May Help Detect Preeclampsia Early

Preeclampsia is a serious condition that can happen during pregnancy. It affects up to 7 out of every 100 pregnant women. It usually starts after 20 weeks and causes high blood pressure, kidney problems, and trouble with blood clotting. If not treated, it can lead to seizures, organ failure, and even death. Each year, about 70,000 women around the world die because of preeclampsia. Right now, doctors give low-dose aspirin to women who might be at risk, but it only works for about half of them. Also, aspirin needs to be started before 16 weeks of pregnancy, before symptoms appear. That’s why it’s very important to find a way to know who is at risk early in pregnancy. A new study led by a Scientist may offer a solution. His team studied blood samples from 57 pregnant women in the first 24 weeks of pregnancy. Later, some of these women developed preeclampsia, and some did not. The scientists looked at special types of fat in the blood, called lipids. They found that women who developed preeclampsia had a different pattern of lipids compared to those who stayed healthy. This pattern is called a lipid signature. This discovery could help doctors create a simple blood test in the future. Such a test would allow them to spot at-risk women early in pregnancy and start monitoring or treatment right away. This could prevent many serious problems and even save lives. This research is still in early stages, but it brings hope for better care and safer pregnancies in the future.

Return to top

 New Blood Test Helps Diagnose Bipolar Disorder

Researchers from the University of Cambridge have discovered a new method to help diagnose bipolar disorder using a combination of an online mental health assessment and a blood test. Many patients with bipolar disorder are misdiagnosed with major depressive disorder, as both conditions can look similar during depressive episodes. However, treatments for the two are very different, and giving the wrong medication to someone with bipolar disorder can make their symptoms worse. In this study, over 3,000 people participated by completing an online questionnaire with more than 600 questions about mood, anxiety, family history, and other psychiatric symptoms. Around 1,000 of them also sent a small blood sample using a simple finger-prick test. Researchers analyzed the blood samples and identified specific biomarkers linked to bipolar disorder. These included markers related to inflammation (e.g., IL-6), oxidative stress (e.g., 8-OHdG), and neuroplasticity (e.g., BDNF - brain-derived neurotrophic factor). These biomarkers were especially associated with manic symptoms—periods of unusually high energy, mood, or activity. The blood test alone could correctly identify about 30% of bipolar cases. When combined with the digital mental health assessment, the accuracy improved significantly. This approach could reduce the delay in correct diagnosis, which often takes years and harms patients' mental well-being. Some patients appreciated the test because it offered a biological explanation for their condition, helping reduce stigma. Researchers believe this method could soon support clinical diagnoses and lead to more personalized treatments. The findings were published in JAMA Psychiatry and mark a significant step toward using biological tools alongside traditional assessments to improve the diagnosis and care of mood disorders like bipolar disorder.

Return to top

Products of SQUARE Pharmaceuticals PLC.

Return to top